BioCryst Pharmaceuticals
BCRX
195 hedge funds and large institutions have $1.65B invested in BioCryst Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 61 increasing their positions, 60 reducing their positions, and 36 closing their positions.
55% more capital invested
Capital invested by funds: $1.06B → $1.65B (+$591M)
19% more call options, than puts
Call options by funds: $81.8M | Put options by funds: $68.5M
17% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 36
3% more funds holding
Funds holding: 190 → 195 (+5)
2% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 60
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.17% less ownership
Funds ownership: 59.07% → 58.9% (-0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$27.3M |
| 2 |
Two Sigma Investments
New York
|
+$24.3M |
| 3 |
Renaissance Technologies
New York
|
+$13.1M |
| 4 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
+$11.4M |
| 5 |
D.E. Shaw & Co
New York
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$45.9M |
| 2 |
HM
HealthCor Management
New York
|
-$22.3M |
| 3 |
Goldman Sachs
New York
|
-$18.5M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$14.3M |
BCRX Hedge Fund Activity: Q2 2021 in Review
195 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2021, worth a combined $1.65B — up 55% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new BCRX positions and 36 closed out — a net gain of 6 holders — while 61 added to existing stakes and 60 trimmed.
The largest buyer was Fisher Asset Management, opening a new position worth an estimated $27.3M. The largest seller was Sarissa Capital Management, cutting an estimated $45.9M.
- 195 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2021, up from 190 in Q1 2021.
- Funds reported $1.65B of BioCryst Pharmaceuticals stock for Q2 2021, up 55% quarter-over-quarter.
- 42 funds opened new BioCryst Pharmaceuticals positions in Q2 2021 and 36 closed out, a net change of +6 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2021 was Fisher Asset Management, an estimated $27.3M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2021 was Sarissa Capital Management, an estimated $45.9M sold.
Based on aggregated 13F filings for Q2 2021.